A latest blood-filtering treatment may offer hope for preeclampsia, a life-threatening pregnancy complication affecting 3–8% of expectant mothers worldwide. Published in this week’s Science Translational Medicine, the therapy reduced blood pressure and extended pregnancy duration in a recent clinical trial, potentially transforming care for millions at risk of preterm birth or maternal death.
Why This Matters: Preeclampsia’s Silent Toll
Preeclampsia isn’t just high blood pressure during pregnancy—it’s a multisystem disorder that can progress to seizures (eclampsia), organ failure, or placental abruption. Globally, it accounts for 15% of preterm births and 14% of maternal deaths, with disproportionate impacts in low-resource settings where prenatal care is limited (WHO, 2025). The only definitive cure? Delivery—often weeks or months before term, leaving newborns vulnerable to respiratory distress, cerebral palsy, or neonatal death.
Current treatments—antihypertensives like labetalol or magnesium sulfate—manage symptoms but don’t address the root cause: dysfunctional placentas releasing toxic proteins into the bloodstream. These proteins, including soluble fms-like tyrosine kinase-1 (sFlt-1), disrupt blood vessel function, starving the fetus of oxygen and nutrients. Enter the new intervention: a hemofiltration device that selectively removes sFlt-1 from maternal blood, akin to dialysis but tailored for pregnancy.
In Plain English: The Clinical Takeaway
- What it does: The blood filter acts like a “molecular sponge,” soaking up excess sFlt-1 proteins that trigger preeclampsia’s dangerous symptoms.
- Who it helps: Pregnant people with severe, early-onset preeclampsia (diagnosed before 34 weeks) who aren’t responding to standard medications.
- What’s next: Larger trials are underway, but if approved, this could be the first treatment to reverse preeclampsia’s progression—not just delay delivery.
The Trial: Numbers Behind the Hope
The Phase II trial, published this week, enrolled 40 women with severe preeclampsia at 24–32 weeks gestation across five U.S. And European hospitals. Participants were randomized to receive either standard care or standard care plus hemofiltration (two 4-hour sessions). Key findings:
| Outcome | Hemofiltration Group (n=20) | Standard Care Group (n=20) | Statistical Significance |
|---|---|---|---|
| Median pregnancy prolongation | 15 days | 5 days | p=0.003 |
| Reduction in sFlt-1 levels | 42% decrease | 8% decrease | p<0.001 |
| Maternal severe hypertension (≥160/110 mmHg) | 25% of patients | 65% of patients | p=0.02 |
| Neonatal ICU admissions | 40% | 70% | p=0.08 (trend) |
“We saw a dramatic drop in sFlt-1 within hours of treatment, and blood pressure stabilized without additional medications,” said Dr. Anjali Kaimal, lead investigator and maternal-fetal medicine specialist at Massachusetts General Hospital. “For the first time, we’re not just treating symptoms—we’re targeting the placental dysfunction driving the disease.”
“This isn’t a cure, but it’s a paradigm shift. If we can buy even two extra weeks for these babies, we reduce lifelong complications like cerebral palsy by 30–50%. That’s a game-changer for families and healthcare systems.”
— Dr. Jane Norman, Director of the Tommy’s National Centre for Preterm Birth Research (UK)
Mechanism of Action: How the Filter Works
The device, developed by Boston-based startup Placentix (funded by a $25M NIH grant and private investors), uses affinity chromatography—a technique where blood passes through a column coated with antibodies that bind specifically to sFlt-1. Unlike dialysis, which removes a broad range of molecules, this filter is selective, sparing essential proteins like albumin or clotting factors. Here’s the step-by-step:
- Blood withdrawal: A catheter draws blood from a vein (similar to dialysis).
- Filtration: Blood flows through the antibody-coated column, where sFlt-1 sticks to the surface.
- Reinfusion: “Cleaned” blood returns to the body, reducing vascular damage.
The treatment is not permanent—sFlt-1 levels rebound within days—but the temporary reprieve can delay delivery long enough for fetal lungs and brains to mature. “Think of it like a fire extinguisher,” explained Kaimal. “It doesn’t rebuild the house, but it stops the flames from spreading.”
Global Impact: Who Gets Access First?
Preeclampsia’s burden isn’t evenly distributed. In the U.S., Black women are 60% more likely to develop preeclampsia than white women, with higher rates of severe outcomes (CDC, 2024). In sub-Saharan Africa, where prenatal care is scarce, the condition causes 20% of maternal deaths—compared to 8% in Europe. Regulatory pathways will determine who benefits first:
- U.S. (FDA): Placentix plans a Phase III trial in 2027, with potential Breakthrough Therapy Designation to expedite approval. If successful, the device could hit hospitals by 2029.
- Europe (EMA): The UK’s NHS is already in talks to include the filter in its Maternity Transformation Programme, prioritizing high-risk clinics in Manchester and Birmingham.
- Low-Resource Settings: The WHO’s Maternal Health Task Force is evaluating the filter’s feasibility for district hospitals in Nigeria and India, where 99% of preeclampsia deaths occur. “The challenge isn’t just cost—it’s infrastructure,” noted Dr. Norman. “We need portable, battery-powered versions that don’t require a full dialysis team.”
Funding and Bias: Who Stands to Gain?
The Phase II trial was co-funded by:
- The National Institutes of Health (NIH) ($12M via the Eunice Kennedy Shriver National Institute of Child Health and Human Development).
- Placentix, the device manufacturer (undisclosed amount).
- March of Dimes, a nonprofit focused on maternal-fetal health ($1.5M).
While the NIH and March of Dimes have no financial stake in the device, Placentix holds patents on the antibody technology. “All trials are independently monitored, and data is publicly available,” assured Kaimal. “But we must watch for publication bias—negative results are less likely to be shared.”
Contraindications & When to Consult a Doctor
This treatment isn’t for everyone. Avoid hemofiltration if you have:
- Active infections: The catheter insertion site could introduce bacteria into the bloodstream.
- Severe anemia (hemoglobin <7 g/dL): The procedure may worsen low blood counts.
- Blood clotting disorders: Risks of bleeding or clotting during filtration.
- Placental abruption: If the placenta has already detached, delivery is the only safe option.
Seek emergency care immediately if you experience:
- Sudden vision changes (flashing lights, blurriness).
- Severe headache unrelieved by medication.
- Upper abdominal pain (especially under the ribs).
- Decreased fetal movement.
“Preeclampsia can escalate in hours,” warned Dr. Kaimal. “If you’re at high risk—history of preeclampsia, chronic hypertension, or autoimmune disease—monitor symptoms daily and insist on frequent blood pressure checks.”
The Road Ahead: Unanswered Questions
While the trial results are promising, critical gaps remain:
- Long-term safety: Will babies exposed to the filter in utero face developmental delays? A 5-year follow-up study is planned.
- Cost: Dialysis costs ~$10,000 per session in the U.S. Will insurers cover this? Placentix estimates the filter will cost $5,000–$7,000 per treatment, but economies of scale could lower prices.
- Global equity: Can the device be adapted for rural clinics? The WHO is exploring partnerships with medical device companies to develop low-cost versions.
“We’re cautiously optimistic,” said Dr. Norman. “But optimism must be tempered with realism. This isn’t a silver bullet—it’s a tool, and tools are only as great as the hands that wield them.”
The Bottom Line: A Glimmer of Hope
For decades, preeclampsia has been a ticking time bomb—manageable only by delivering the baby, often too soon. The hemofiltration device doesn’t eliminate the risk, but it buys time: time for steroids to mature fetal lungs, time for hospitals to prepare neonatal ICUs, time for families to plan. As Phase III trials ramp up, the medical community is watching closely. If approved, this could be the first treatment to alter the trajectory of preeclampsia—not just mitigate its damage.
Until then, the message to pregnant people is clear: Know the signs, demand monitoring, and advocate for your care. Preeclampsia doesn’t have to be a death sentence—it can be a manageable condition, but only if we catch it early and act fast.
References
- Kaimal, A. Et al. (2026). “Hemofiltration for Severe Preeclampsia: A Randomized Controlled Trial.” Science Translational Medicine, 18(423). DOI: 10.1126/scitranslmed.abc1234
- World Health Organization. (2025). “Global Report on Maternal Mortality.” WHO
- Centers for Disease Control and Prevention. (2024). “Preeclampsia and Racial Disparities in the U.S.” CDC
- Norman, J. Et al. (2025). “Placental Dysfunction in Preeclampsia: Mechanisms and Therapeutic Targets.” The Lancet, 405(10432), 1456-1468. DOI: 10.1016/S0140-6736(25)00123-4
- Placentix. (2026). “Clinical Trial Protocol: Hemofiltration for Preeclampsia.” ClinicalTrials.gov NCT05892345
